** Shares of drugmaker Alkermes ALKS.O rise 6.38% to $34
** Co posts Q4 sales of $430 million, beating analysts' estimate of $379 million - LSEG
** Sees 2025 revenue between $1.3 billion and $1.4 billion vs est $1.4 billion
** Expects mid-stage study data of neurological disorder drug in H2 2025
** Plans to begin early-stage study of drugs to treat sleep disorders
** In the last 12 months, ALKS rose 7.6%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。